BamSEC and AlphaSense Join Forces
Learn More

SELLAS Life Sciences Group Inc.

NASDAQ: SLS    
Share price (1/3/25): $1.08    
Market cap (1/3/25): $76.0 million

Material Contracts Filter

EX-10.1
from 8-K 2 pages October 2, 2024 SELLAS Life Sciences Group, Inc. 7 Times Square, 25th Floor, New York Ny 10036 Re: Time Square Tower, 7 Time Square, New York, Ny (The “Building”) Ladies and Gentlemen
12/34/56
EX-10.1
from 8-K 29 pages Securities Purchase Agreement
12/34/56
EX-10.51
from 10-K 15 pages Separation Agreement and General Release
12/34/56
EX-10.50
from 10-K 15 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because SELLAS Life Sciences Group, Inc. Has Determined the Information (I) Is Not Material and (II) the Company Customarily Treats That Information as Private. Date Provided to Employee: March 8, 2024 Confidential Separation Agreement and General Release
12/34/56
EX-10.49
from 10-K 3 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because SELLAS Life Sciences Group, Inc. Has Determined the Information (I) Is Not Material and (II) the Company Customarily Treats That Information as Private. February 25, 2022
12/34/56
EX-10.1
from 8-K 39 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 44 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 6 pages Second Amendment to Sublease
12/34/56
EX-10.1
from 8-K 37 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 10-Q 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because SELLAS Life Sciences Group, Inc. Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to SELLAS Life Sciences Group, Inc. if Publicly Disclosed Addendum to the Side Letter Agreement Between 3d Medicines Inc. and SELLAS Life Sciences Group, Inc
12/34/56
EX-10.1
from 10-Q 20 pages SELLAS Life Sciences Group, Inc. 2023 Amended and Restated Equity Incentive Plan Amended and Restated on June 20, 2023
12/34/56
EX-10.1
from 10-Q 6 pages March 14, 2022 1. Severance
12/34/56
EX-10.39
from 10-K 5 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because SELLAS Life Sciences Group, Inc. Has Determined the Information (I) Is Not Material and (II) Would Likely Cause Competitive Harm to SELLAS Life Sciences Group, Inc. if Publicly Disclosed Side Letter Agreement Between 3d Medicines Inc. and SELLAS Life Sciences Group, Inc.,
12/34/56
EX-10.1
from 8-K 3 pages SELLAS Life Sciences Group, Inc. Amendment to the Common Stock Purchase Warrant
12/34/56
EX-10.1
from 10-Q 37 pages License Agreement
12/34/56
EX-10.36
from 10-K 7 pages Pursuant to Item 601(b)(10)(iv) of Regulation S-K, Certain Identified Information Marked With [***] Has Been Excluded From the Exhibit, Because It Is Both Not Material and Is the Type of Information That the Registrant Treats as Private or Confidential. First Amendment to Sublease
12/34/56
EX-10.1
from 8-K 6 pages December 14, 2021 1. Severance
12/34/56
EX-10.1
from 10-Q 8 pages SELLAS Life Sciences Group, Inc. Employee Stock Purchase Plan
12/34/56
EX-10.50
from 10-K 6 pages SELLAS Life Sciences Group, Inc. Times Square Tower 7 Times Square, Suite 2503 New York, New York 10036 January 19, 2021
12/34/56
EX-10.1
from 8-K/A 71 pages Exclusive License Agreement by and Between SELLAS Life Sciences Group, Inc., Slsg Limited, LLC, and 3d Medicines Inc. December 7, 2020
12/34/56